Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 11/8/2014 |
| Start Date: | March 2014 |
| End Date: | August 2014 |
| Contact: | Hideyuki Yamamoto |
| Email: | yamamotoh@akrospharma.com |
| Phone: | 609-919-6111 |
Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)
The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics)
of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to
evaluate the effect of food on the PK of JTT-251 in healthy subjects.
of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to
evaluate the effect of food on the PK of JTT-251 in healthy subjects.
Inclusion Criteria:
Healthy Subject Cohorts:
- Healthy male or female subjects
- Body Mass Index (BMI) between 19.0 and 31.0 kg/m2 (inclusive)
Type 2 Diabetic Subject Cohorts:
- Male or female Type 2 diabetic subjects diagnosed for at least 3 months
- BMI between 25 and 40 kg/m2 (inclusive)
- Have a glycosylated hemoglobin (HbA1c) of >6.5% to ≤10.9% (inclusive) if treatment
naïve with respect to hypoglycemic agents OR >6.5% to ≤10.0% (inclusive) if treated
with metformin
Exclusion Criteria:
Healthy Subject Cohorts:
- Known clinically relevant history or presence of significant respiratory,
gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,
cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
metabolic, and dermatological or connective tissue disease
- Subjects with a systolic blood pressure >150 mmHg and/or diastolic blood pressure >90
mmHg
Type 2 Diabetic Subject Cohorts:
- Subjects with a known medical history or presence of type 1 diabetes mellitus
- Subjects with known medical history of acute metabolic diabetic complications
- Subjects with uncontrolled hypertension (systolic blood pressure >160 mmHg and/or
diastolic blood pressure >95 mmHg with documented ongoing treatment)
We found this trial at
1
site
Click here to add this to my saved trials
